The COVID‐19 pandemic has presented significant challenges for Dermatology services, particularly the diagnosis and management of malignant melanoma (MM). Early detection and definitive surgical treatment are key to improving MM prognosis, and in England there is a suspected skin cancer referral pathway that facilitates specialist Dermatology assessment within two weeks. Here, we describe the impact of COVID‐19 on MM detection, based on data from the a Dermatology Department in central London.
Melanoma defies ‘lockdown’: ongoing detection during Covid‐19 in central London